Loading stock data…
RXST
$5.69+0.14 (+2.52%)
Market OpenUpdated 10:48 AM EDT
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
RxSight, Inc. in the Healthcare sector is trading at $5.55. Wall Street consensus targets $8.79 (7 analysts), implying a +58.3% move over the next 12 months. The stock is currently near its 52-week low of $5.30, remaining 36.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +58.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$5.69
Potential Downside
0%
Whystock Fair Value$5.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Hold
Mean target$8.79+54.4%
Range$7.50 – $11.00
Fundamentals
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that ena...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$305.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.70%
Volume
Today's trading volume
80,312
Recent News
RxSight (RXST) Q1 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? Ronald Kurtz: Good afternoon, everyone, and thank you for joining us today. Before Mark takes us through the Q1 numbers, I'd like to provide an overview of our commercial progress, starting with the Annual Meeting of the American Society of Cataract and Refractive Surgery held just a few weeks ago in Washington, D.C. As the largest U.S. meeting focused on refractive and premium cataract surgery, RxSight's light adjustable lens technology continued to be a key focus for doctors.
RxSight, Inc. Q1 2026 Earnings Call Summary
Moby summary of RxSight, Inc.'s Q1 2026 earnings call
RxSight Q1 Earnings Call Highlights
RxSight (NASDAQ:RXST) executives said the company is seeing early signs that customer re-engagement efforts are helping stabilize utilization of its Light Adjustable Lens (LAL) platform, even as first-quarter revenue declined year over year due to lower sales of its Light Delivery Device (LDD) capit
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of -58.33% and +4.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets
RxSight’s modeled fair value is steady at US$9.93, closely tracking analyst price targets that cluster in the US$9 to US$10 range. Bullish and bearish commentary around the new 2026 revenue outlook, recent target cuts to the high single digits, and a mix of Neutral and Hold ratings all help explain why that target band has stayed tight rather than moving sharply in either direction. As you read on, you will see how these shifting views and model tweaks can help you follow the evolving story...